STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer
View abstract on PubMed
Summary
This summary is machine-generated.Signal transducer and activator of transcription 3 (STAT3) may predict pembrolizumab efficacy in advanced urothelial carcinoma (UC). High STAT3 or phosphorylated STAT3 (p-STAT3) expression is linked to better outcomes, suggesting STAT3
Area Of Science
- Oncology
- Immunotherapy
- Molecular Biology
Background
- Advanced urothelial carcinoma (UC) requires improved second-line therapies.
- Pembrolizumab shows promise, but predictive biomarkers are needed to optimize patient selection.
- Signal transducer and activator of transcription 3 (STAT3) is a potential biomarker.
Purpose Of The Study
- To evaluate the predictive value of STAT3 expression for pembrolizumab response in advanced UC.
- To elucidate the role of STAT3 in mediating treatment efficacy.
- To identify patients likely to benefit from pembrolizumab therapy.
Main Methods
- Retrospective analysis of 31 advanced UC patients treated with pembrolizumab.
- Assessment of STAT3, phosphorylated STAT3 (p-STAT3), and PD-L1 expression via tissue microarrays.
- Correlation analysis of biomarker expression with overall survival (OS) and in vitro functional assays.
Main Results
- High STAT3 or p-STAT3 expression was associated with improved prognosis in most patients (n=25).
- A subset of patients (n=6) with high STAT3/p-STAT3 and high platelet-to-lymphocyte ratio (PLR) had shorter OS.
- STAT3 partially mediated interferon-gamma (IFN-γ)-induced apoptosis in bladder cancer cell lines.
Conclusions
- STAT3 plays a crucial role in mediating pembrolizumab efficacy in advanced UC.
- STAT3 influences apoptosis in response to IFN-γ, impacting treatment outcomes.
- STAT3 expression may serve as a predictive biomarker for pembrolizumab therapy in UC.

